Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Firefly molecule could quickly shed light on how well new drugs work

18.12.2002


Faint glow given off only when cells are killed could speed drug development for cancer, stroke, other diseases



The process that makes fireflies glow bright in the summer night can also shed light on how well new medicines work, showing immediately whether the drugs are effective at killing cells or causing other effects.

That’s the conclusion of a team of scientists from the University of Michigan Health System, who report that they have inserted the gene for a firefly’s glow-producing molecule into mice with cancer, and kept it from producing its telltale beacon of light until the cells started to die in response to cancer treatment.


Using a highly sensitive camera, the researchers were able to immediately detect the faintest traces of the firefly light as it passed outside the bodies of the mice.

The findings, published in the Dec. 24 issue of the Proceedings of the National Academy of Sciences and posted online last week, promises to give researchers a new way to get real-time information on whether new medicines are working.

It could be used to speed up the testing of new drugs for cancer, stroke, AIDS, auto-immune disorders, blood diseases, heart attack damage, nerve-degenerative diseases like Alzheimer’s disease, and other disorders where drugs are needed to kill cells, or to stop cell death. It could also be used to monitor other cell processes.

"This is the first time anyone has been able to make real-time images of apoptosis -- the process of cell death that is so important to so many diseases and treatments," says lead author Alnawaz Rehemtulla, Ph.D., associate professor of radiation oncology at the U-M Medical School and co-director of the U-M Center for Molecular Imaging. "This proves that we can see what’s going on at the molecular level while the drugs are working, giving results in days or weeks instead of months or years.’

The process is made possible through the use of luciferase, the enzyme that triggers a chemical process that lights up the tails of fireflies. The light-emitting process, called bioluminescence, has been used for several years in biomedical research -- but with the glow always turned "on" to produce a constant stream of light.

The U-M team, led by Rehemtulla and Brian D. Ross, Ph.D., professor of radiology and co-director of the center, reports they have discovered a way to turn the light "off" until a drug causes a cell to start dying.

They did this by attaching luciferase to another protein, a portion of the receptor for the hormone estrogen. The estrogen receptor, or ER, is known to squelch the action of attached proteins, such as luciferase’s light-releasing chemical reaction.

Then, they added a "switch" that could turn the luciferase on -- but only when the cell was in the self-destruction process called apoptosis.

The ability to make images of apoptosis in real time could help pharmaceutical companies and academic researchers screen new drugs rapidly, for all types of diseases that are characterized by over-growing cells – or cells that die too soon.

For example, scientists are studying drugs that can keep brain cells from dying after a stroke, a process that occurs through apoptosis and can cause permanent disability. Conversely, cancers and blood disorders that stem from over production of certain cell types are often treated with drugs aimed at killing extra cells.

But the U-M team believes its technique could also help with drug discovery and testing in diseases where other molecular mechanisms besides apoptosis are involved.

The team’s discovery hinges on the ability to turn the luciferase glow off until a cell process occurs. They developed this "light switch" by inserting a tiny section of protein between the luciferase and the estrogen receptor (ER) protein. Called DEVD, the section is known to be targeted for cutting by an enzyme called caspase-3 -- the key agent that sets off apoptosis. Because caspase-3 is most active when cells are dying, the team felt that it would cut the DEVD site on their luciferase-ER complex, allowing light to escape, if a cell-killing drug was working.

They were right. In the new report, the team shows that the luciferase-DEVD-ER complex released much less light than luciferase alone in either cell cultures or in mice with cancer that had been injected with a DNA sequence encoding the complex. When they added another ER and DEVD to the other side of the luciferase, the amount of light emitted was cut even further.

But when the researchers added an experimental cancer-fighting drug called TRAIL, which is known to cause apoptosis, it was just like turning on a light switch.

As the drug caused the activation of the caspase-3 enzyme, the bonds between the luciferase and its light-hiding companion ER molecules were cut at the DEVD cleavage site, and the light-emitting process began. One hour after TRAIL treatment, the amount of light emitted from the mice had gone up by 186 percent. Mice that received a placebo instead of TRAIL emitted only about 21 percent more light than they had before.

Even though only a few photons, or particles of light, can escape a mouse body from the glowing luciferase, the researchers were able to detect them with a bioluminescence imaging camera that can detect single photons.

The camera, which is kept in a light-proof chamber at ultra-cold temperatures to keep out all stray energy, produced vivid images showing the intensity of light -- and therefore the rate of cell death -- in different regions of the cell cultures or mouse cancer tumors. Rehemtullah notes that the technology is sensitive enough to pick up cell death in areas as small as 100 cells.

"The enzyme was turned on in a protease-dependent manner, and though we used caspase-3 in this instance, we believe it could be any protease that’s important to any cellular process," Ross emphasizes. "And, we believe other reporters could be used, including radioactive positron-emitting molecules that can be imaged using PET scanning." He noted that preliminary work on these approaches, and efforts to develop a transgenic strain of mice containing the genes for the luciferase complex, is already under way at UMHS.

The research was funded by the National institutes of Health through grants supporting the Center for Molecular Imaging, and by the Michigan Life Sciences Corridor.


The U-M has applied for a patent on the technique, and licensed it to a local biotechnology company, Molecular Therapeutics, Inc. Both Rehemtulla and Ross hold key positions at Molecular Therapeutics (www.moleculartherapeutics.com).

Other authors are former postdoctoral fellow Bharathi Laxman, Ph.D., research associate Daniel Hall, research fellow Mahaveer Swaroop Bhojani, radiation oncology resident Daniel Hamstra, and radiology professor Thomas Chenevert, Ph.D.

Reference: Proceedings of the National Academy of Sciences, Dec. 23, 2002, Vol. 99, No. 26, pp. 16551–16555 or www.pnas.org/cgi/content/abstract/252644499v1.

Kara Gavin | EurekAlert!
Further information:
http://www.pnas.org/cgi/content/abstract/252644499v1

More articles from Health and Medicine:

nachricht Hot cars can hit deadly temperatures in as little as one hour
24.05.2018 | Arizona State University

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Powerful IT security for the car of the future – research alliance develops new approaches

The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.

Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

In focus: Climate adapted plants

25.05.2018 | Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

 
Latest News

In focus: Climate adapted plants

25.05.2018 | Event News

Flow probes from the 3D printer

25.05.2018 | Machine Engineering

Less is more? Gene switch for healthy aging found

25.05.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>